An observational study in Obesity, Metabolic Syndrome and Insulin Resistance, sponsored by Istanbul University. Completed. Open to participants aged 18 Days to 65 Days. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Istanbul University · Observational
This study evaluated the prognostic value of preoperative pentraxin-3 (PTX3) levels in predicting weight loss, inflammatory resolution (CRP, IL-6), and metabolic improvements (HOMA-IR) following Roux-en-Y gastric bypass in patients with obesity.
This single-center longitudinal study was conducted at Istanbul University Hospital. A total of 23 patients undergoing primary Roux-en-Y gastric bypass were included. PTX3 levels were measured preoperatively, and patients were stratified according to a data-derived cut-off (\~21.7 ng/mL). Outcomes assessed at baseline, 3 months, and 6 months included body weight, BMI, excess weight loss (%EWL), fasting insulin, HOMA-IR, CRP, and IL-6. The primary hypothesis was that preoperative PTX3 would predict postoperative CRP normalization and insulin resistance improvement.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 23 is below the median of 135 across 1,283 observational studies indexed under Obesity.
Browse Obesity studies →Istanbul University is the lead sponsor of 496 studies on the registry; 79 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adults with obesity scheduled to undergo primary Roux-en-Y gastric bypass at Istanbul University Hospital.
Sexes Eligible for Study: All Gender-Based: No Accepts Healthy Volunteers: No
Exclusion Criteria:
Participants with preoperative serum PTX3 levels ≥21.7 ng/mL. All patients underwent Roux-en-Y gastric bypass and were followed prospectively for 6 months with metabolic and inflammatory assessments.
Other: Biomarker Stratification by PTX3
Participants with preoperative serum PTX3 levels \<21.7 ng/mL. All patients underwent Roux-en-Y gastric bypass and were followed prospectively for 6 months with metabolic and inflammatory assessments.
Other: Biomarker Stratification by PTX3
Participants were stratified into groups according to preoperative serum PTX3 levels (≥21.7 ng/mL vs. \<21.7 ng/mL). All participants underwent Roux-en-Y gastric bypass and were prospectively evaluated for metabolic (HOMA-IR, %EWL) and inflammatory (CRP, IL-6) outcomes during 6 months of follow-up.
Also known as: Pentraxin-3 (PTX3) Grouping
Change in HOMA-IR from baseline to 6 months
Assessment of the improvement in insulin resistance after Roux-en-Y gastric bypass, measured by the homeostasis model assessment of insulin resistance (HOMA-IR). Preoperative PTX3 stratification will be used to evaluate predictive value.
Time frame: Baseline, 3 months, 6 months
Percent Excess Weight Loss (%EWL) at 6 months
Evaluation of weight loss outcomes after surgery, calculated as percent excess weight loss (%EWL). Comparisons will be made between PTX3 high vs. low groups.
Time frame: 6 months
CRP normalization at 6 months
Proportion of patients achieving CRP ≤5 mg/L after surgery. Predictive value of baseline PTX3 will be assessed.
Time frame: 6 months
Change in IL-6 from baseline to 6 months
Change in serum IL-6 levels after surgery, analyzed between PTX3 high vs. low groups.
Time frame: Baseline, 3 months, 6 months
No study locations are listed for this record.
Plan to share: No — The study team does not plan to share individual participant data at this time.
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul University